Cancer Research UK

What Cancer Research UK does

Cancer Research UK is the world's leading cancer charity, tracing its origins to 1902 (founding of the Imperial Cancer Research Fund) and formally established in its current form in 2002 through the merger of the Imperial Cancer Research Fund and the Cancer Research Campaign. Registered as a charity in England and Wales, it operates a UK-headquartered research and public engagement enterprise with offices and institutes in London, Cambridge, Manchester, Glasgow, Oxford, and Newcastle, supported by a workforce of 4,000+ scientists, doctors, and nurses. Its core offering spans patient information services (the About Cancer platform covering 200+ cancer types, a clinical trials database, the Cancer Chat forum, and a nurse helpline), a translational research arm (Cancer Research Horizons), four core research institutes, seven translational research centres, and the Centre for Drug Development for early-phase clinical trials. The technology stack includes a £60 million Data Science in Cancer Research strategy with the AI Research Alliance, Project AURORA AI co-scientist, AI-powered liquid biopsy (Ewing sarcoma detection), and pilot deployment of Illumina's StrataMap Spatial Solution for spatial transcriptomics at the Cambridge Institute.

The organisation's business model is a diversified charity revenue engine combining recurring individual giving (£79m in regular gifts), event-based fundraising (Race for Life, Shine Night Walk, Big Hike generating £17.1m from 90,375 supporters in 2023/24), a UK-wide charity shop and superstore retail network (88 closures planned by May 2026 with 12 new superstores by 2028), a weekly lottery, legacy gifts, and corporate partnerships (ScottishPower, Tesco, Channel 4, UCB). The customer base spans four primary segments: the general public (information users and supporters), donors and fundraisers, healthcare professionals, and cancer researchers receiving grants and infrastructure access. Go-to-market is community-led and direct-to-consumer, supplemented by channel partnerships (Tesco pharmacist training in 350+ stores) and a global research alliance through Cancer Grand Challenges with the US National Cancer Institute across 34 institutions in 9 countries. The committed £1.5 billion research investment for 2022-2027 anchors an ambitious growth and impact trajectory aimed at improving cancer survival from 2-in-4 to a target of 3-in-4 by 2034.

Name

Cancer Research UK

Legal name

Cancer Research UK

Website

https://cancerresearchuk.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cancer Research UK is the world's leading cancer charity, funding research into all 200 cancer types through 4,000+ scientists across UK institutes. It serves patients, donors, healthcare professionals, and researchers via £419m+ annual research investment, public engagement, and a national charity shop network.

Ownership category

akta.pro rank

Product category

Charitable Cancer Research Services

NAICS

Voluntary Health Organizations (813212), Grantmaking Foundations (813211), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Cancer research funding
• Charitable fundraising
• Patient cancer information
• Clinical trials research
• Translational oncology

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Individual Donations: One-time and recurring donations from individual supporters, including monthly Direct Debit giving programmes. In 2023/24, £79m was received through regular gifts, enabling long-term research commitments.
2. Charity Retail: High street shops and superstores selling donated pre-loved items. The charity announced closures of 88 shops by May 2026 to improve efficiency while opening 12 new superstores by 2028.
3. Events and Fundraising: Revenue from events including marathons, sponsored walks, and challenge events. 90,375 supporters took part in social fundraising challenges raising £17.1m in 2023/24.
4. Legacy Gifts: Bequests and gifts left in wills by supporters to fund cancer research in perpetuity.
5. Lottery: Weekly lottery programme where supporters can participate with proceeds funding research.
6. Corporate Partnerships: Partnerships with corporations including ScottishPower (£4 million committed over 5 years for lung cancer research) and others for research funding and cause marketing.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels11 records

Core offering

Cancer Research UK is a registered charity that funds cancer research across more than 200 cancer types through research grants, dedicated research institutes, and translational partnerships, while also providing patient-facing information and support services, running mass-participation fundraising events, and operating a national chain of charity retail shops. The organization invests hundreds of millions of pounds annually in research and runs programs that span basic discovery, biomarker development, drug development, and clinical trials.

Product overview

Cancer Research UK operates as a charitable organization offering a portfolio of patient information services, research funding programs, and public engagement initiatives rather than a commercial product company. The core offering consists of the 'About Cancer' patient information platform (covering symptoms, treatments, causes, and coping strategies for 200+ cancer types), a clinical trials database, and community support tools including the Cancer Chat forum and nurse helpline. Fundraising products include retail shops, events (Race for Life, Shine Night Walk, Big Hike), and branded campaigns (Stand Up To Cancer, Bowel Babe Fund). Research infrastructure comprises Cancer Research Horizons (translational arm), the Centre for Drug Development, four core institutes (Scotland, Cambridge, Manchester, London), and seven translational research centres. Public engagement includes The Rest Is Science podcast (with Goalhanger) and Cancer Detectives documentary series (with Channel 4). The organization has recently launched a £60 million Data Science in Cancer Research strategy incorporating AI capabilities through Project AURORA and the AI Research Alliance.

Differentiator

Problem solved

Functional benefit

Brands

• Race for Life: Fundraising event series for cancer research
• Stand Up To Cancer
• Bowel Babe Fund
• Bobby Moore Fund
• Cancer Research UK for Children & Young People
• Cancer Research Horizons
• MAP Congress

Products and services

• About Cancer Patient Information Service

Quantifiable outcome

• UK cancer death rate fell 29% from peak in 1989
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered minor and core.

• TescominorChannel Partner/ Reseller/ Distributor · 29 June 2026Partnership to train pharmacists in over 350 Tesco stores to help identify potential cancer symptoms and guide people on next steps without needing a GP appointment.
• GoalhangerminorGTM or Marketing Partner · 22 June 2026Partnership producing 'The Rest Is Science' podcast with Hannah Fry and Michael Stevens exploring science and research driving cancer understanding.
• UCBcoreStrategic or Co-development Partner · 7 May 2026Strategic oncology alliance combining UCB's antibody discovery capabilities with Cancer Research UK's translational research infrastructure and Cancer Research Horizons' innovation network to accelerate novel cancer therapy development.
• Children's National HospitalcoreStrategic or Co-development Partner · 8 April 2026Led by Cancer Grand Challenges NexTGen team for international CAR T-cell clinical trial for solid tumors in children. US arm led from this institution alongside Dana-Farber Cancer Institute and Boston Children's Hospital.
• UCL and Great Ormond Street HospitalcoreStrategic or Co-development Partner · 8 April 2026UK arm of Cancer Grand Challenges NexTGen team leading international CAR T-cell clinical trial for solid tumors in young patients.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 4 March 2026Co-founded Cancer Grand Challenges initiative. $125 million commitment funding five international research teams with up to $25 million each over five years to tackle ambitious questions in cancer research.
• Stand Up To Cancer (SU2C)coreStrategic or Co-development Partner · 8 January 2026Extended funding of $3 million for SU2C Gastric Cancer Interception Dream Team to launch clinical trial testing fluorescence-guided endoscopy for early gastric cancer detection, spanning US, UK, and South Korea institutions.
• Aleta BiotherapeuticsminorStrategic or Co-development Partner · 8 December 2025Partnership through Cancer Research UK Centre for Drug Development for Phase I/II trial of ALETA-001 in patients with relapsed/refractory B-cell malignancies previously treated with CD19 CAR T-cell therapy.
• ScottishPowercoreStrategic or Co-development Partner · 21 November 2025Partnership renewal for lung cancer research. ScottishPower committed up to £4 million over five years to support the Lung Cancer Centre of Excellence and develop early detection models. Over £40 million raised since 2012 partnership began.
• Nxera PharmaminorStrategic or Co-development Partner · 21 October 2025Phase 1 trial collaboration for oral EP4 antagonist HTL0039732, with encouraging results presented at ESMO 2025 showing safety confirmation and partial responses in resistant tumors.
• Channel 4coreStrategic or Co-development Partner · 16 October 2025Collaboration to produce documentary series 'Cancer Detectives: Finding the Cures' showcasing cancer research innovations and personal stories to raise public awareness and engagement.
• KisoJi BiotechnologyminorStrategic or Co-development Partner · 2 December 2024Partnership for clinical development of KisoJi's lead antibody KJ-103 for solid tumors using AI-powered antibody discovery platform. KisoJi raised $41 million with partnership establishing clinical development pathway.

Scale indicators28 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• American Cancer Society: The largest voluntary health organisation in the US focused on cancer, funding research, providing patient information, and running large-scale fundraising campaigns. Directly comparable in mission, donor base, and translational model to CRUK's UK operations.
• Macmillan Cancer Support: UK-based cancer charity providing practical, emotional, and financial support to people affected by cancer. Direct peer in the UK charity ecosystem with overlapping donor pool, fundraising event portfolio (e.g., World's Biggest Coffee Morning), and policy advocacy function.
• Cancer Research Institute: US-based nonprofit exclusively funding cancer immunology research and immuno-oncology. Comparable as a disease-specific cancer research charity with translational funding programmes and clinical trial co-development.
• Leukaemia & Lymphoma Society: US-based voluntary health organisation funding blood cancer research and providing patient support. Comparable disease-specific cancer charity with established peer-reviewed grant programmes and a major fundraising infrastructure.
• Marie Curie: UK charity providing care and support for people with terminal illness including cancer. Comparable in UK charity retail footprint, hospice funding model, and donor demographics, though with a stronger palliative-care focus than CRUK's research orientation.
• Susan G. Komen: The world's largest breast cancer charity, funding research and running major awareness/fundraising campaigns (e.g., Race for the Cure). Highly comparable in mission, donor events, and translational research funding, serving as a US analogue to CRUK's single-disease research focus.

Broad incumbents

• Wellcome Trust: One of the world's largest charitable foundations, funding health research including significant cancer research. Comparable as a UK-based health-research grantmaking foundation with similar scale, long-duration funding model, and translational ambitions.
• British Heart Foundation: UK's largest charity funding cardiovascular research with a high-street charity shop network similar to CRUK's. Comparable in operating model (research funding + charity retail + legacy giving) and UK donor base, though focused on a different disease area.
• National Cancer Institute: The US federal government's principal agency for cancer research and training. Direct co-founding partner in Cancer Grand Challenges, and the world's largest public funder of cancer research — a natural peer in mission and translational pipeline.

Emerging players

• Francis Crick Institute: London-based biomedical discovery institute where CRUK is a founding partner and operates a research facility. Comparable as a translational cancer research organisation with overlapping scientific leadership and shared infrastructure.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks3 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/CancerResearchUK
• Instagraminstagram.com/cancerresearchuk
• TikToktiktok.com/@cancerresearchukshops
• Xx.com/CR_UK
• Facebookfacebook.com/cancerresearchuk
• LinkedInlinkedin.com/company/cancer-research-uk

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Research UK